MaxCyte reported preliminary Q3 2026 core business revenue of $8.1 million, a 26% year-over-year increase. The company subsequently raised its full-year 2026 revenue guidance to $34 million, up from $30-$32 million, driven by increased core business and SPL Program-related revenue, indicating stronger-than-expected performance and positive future outlook.
MaxCyte announced preliminary Q3 2026 core business revenue of $8.1 million, representing a robust 26% year-over-year growth. This strong performance has led the company to raise its full-year 2026 revenue guidance significantly, from $30-$32 million to $34 million. The increase is attributed to both an improved outlook for its core business revenue (now $28 million) and higher anticipated SPL Program-related revenue ($6 million). This news is a positive catalyst for MXCT, suggesting stronger operational execution and demand for its cell-engineering platform technologies. Short-term, this could lead to increased investor confidence and a potential stock price rally. Long-term, sustained growth in core business and successful monetization of SPL programs are key opportunities for traders.